

Supplemental Figure 1. HuMax-IL8 neutralizes IL-8 in claudin-low TNBC cells. Cytokine/chemokine array and quantification of chemokines that bind CXCR1/2 in MDA-MB-231 and MDA-MB-436 cells. Shown in the graphs is the ratio of indicated chemokines detected in the supernatant of HuMax-IL-8/IgG treated cultures. Quantification was done via ImageJ binary pixel intensity. [G1: ENA-78 (CXCL5); J1: GROα/β/γ; K1: GROα; J2: IL-8 (CXCL8); G6: GCP2 (CXCL6); J7: NAP-2 (CXCL7)].



Supplemental Figure 2. HuMaxIL-8 reduces mesenchymalization of claudin-low TNBC cells *in vitro*. BT549 cells were treated with control IgG or HuMax-IL-8 (25 μg/ml) for 3 days. Images show expression of E-cadherin and fibronectin (green); blue corresponds to 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei. Original magnification of all images: 20X; scale bars: 75 μm. Right graph corresponds to the quantification of green fluorescence (E-cadherin and fibronectin, respectively) utilizing ImageJ binary pixel intensity analysis (n = 2, per cell line per condition; data representative of 2 experiments). Box shows the ratio of E-cadherin/fibronectin (E/F) expression in IgG vs. HuMax-IL8 treated cells. Data in each graph represent mean (bars) + SEM (error bars) from 2 experimental replicates (dots). Differences between means were compared using the two-tailed unpaired *t*-test for each cell line. (*$P < 0.05$; **$P < 0.01$).



Supplemental Figure 3. HuMaxIL-8 reduces features of mesenchymalization as a monotherapy and in combination with chemotherapy. Expression of epithelial E-cadherin (*left panels*) and mesenchymal vimentin (*right panels*) on MDA-MB-231 xenografts treated with HBSS (control), docetaxel (10 mg/kg), HuMax-IL8 (200 μg), or the combination docetaxel and HuMax-IL8. Original magnification of all images is 20X; scale bars: 75 μm.

Supplemental Table 1. Expression of immune relevant surface molecules in triple negative breast cancer cell lines treated in culture with HuMax-IL8 vs. IgG antibody.

Marker	MDA-MB-231		BT549		Hs578T	
	IgG	HuMax	IgG	HuMax	IgG	HuMax
HLA-ABC	99.6 (243)	95.8 (167)	90.5 (136)	81.3 (99)	87.3 (97)	75.1 (64)
MICA	63.6 (44)	66.2 (47)	64.4 (48)	69.5 (44)	97.2 (100)	94.1 (60)
CD54	93.4 (196)	92.1 (217)	88.5 (254)	92.3 (399)	69.4 (77)	66.3 (48)
CD58	99.9 (1381)	99.9 (1475)	99.7 (357)	99.8 (269)	100.0 (693)	100.0 (631)
CD80	3.9 (21)	8.4 (18)	1.1 (134)	2.4 (40)	10.2 (23)	5.2 (17)
PD-L1	98.9 (177)	99.3 (232)	57.6 (52)	66.2 (50)	96.1 (146)	96 (102)



Supplemental Figure 4. IL-8 blockade with HuMax-IL8 increases expression of molecules involved in antigen-processing and TRAIL receptors. Quantification of (A) TAP1, TAP2, TAPASIN and (B) TRAIL-R1 and TRAIL-R2 mRNA levels in MDA-MB-231 cells after treatment with control IgG or HuMax-IL8 (25 μg/ml) for 3 days. Data in each graph represent mean (bars) + SEM (error bars) from 2-3 replicates. Differences between means were compared using two-tailed unpaired *t*-test for each cell line. (**$P < 0.01$; ***$P < 0.001$).